Schonfeld Strategic Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59,107	Closed	-$521K	–	2713
2025 Q4	$521K	Buy	+59,107	New	+$325K	﹤0.01%	1379
2025 Q2	–	Sell	-379,001	Closed	-$1.74M	–	2577
2025 Q1	$1.74M	Buy	379,001 +108,460	+40%	+$506K	0.01%	1021
2024 Q4	$1.3M	Buy	+270,541	New	+$1.3M	0.01%	1012
2023 Q4	–	Sell	-22,241	Closed	-$96.1K	–	2254
2023 Q3	$96.1K	Buy	+22,241	New	+$124K	﹤0.01%	1499
2022 Q4	–	Sell	-49,991	Closed	-$494K	–	3043
2022 Q3	$494K	Buy	+49,991	New	+$528K	﹤0.01%	1762
2021 Q4	–	Sell	-10,000	Closed	-$172K	–	2571
2021 Q3	$172K	Buy	+10,000	New	+$175K	﹤0.01%	1812
2020 Q1	–	Sell	-14,284	Closed	-$235K	–	1550
2019 Q4	$235K	Buy	+14,284	New	+$216K	0.01%	1095
2016 Q4	–	Sell	-43,169	Closed	-$719K	–	658
2016 Q3	$719K	Buy	+43,169	New	+$581K	0.12%	227

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's VNDA Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 59,107 shares — an estimated $521K sold.

Schonfeld Strategic Advisors first reported a position in VNDA in Q3 2016 and held it in 8 quarters. The position peaked at $1.74M in Q1 2025. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 59,107 Vanda Pharmaceuticals shares in Q1 2026, an estimated $521K.
Schonfeld Strategic Advisors first reported a position in Vanda Pharmaceuticals in Q3 2016 and held it in 8 quarters.
Schonfeld Strategic Advisors's Vanda Pharmaceuticals position peaked at $1.74M in Q1 2025.
171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.